• January 9, 2015

    Press Release Spotlight

    Stealth Biotherapeutics Expands Clinical Development for Mitochondrial Therapies

    Read the full article

    Funding grows to more than $100M Boston, MA January 9, 2015—(BUSINESS WIRE)—Stealth BioTherapeutics (formerly Stealth Peptides), a clinical-stage biopharmaceutical company developing drug candidates for the treatment of diseases involving mitochondrial dysfunction, today detailed its clinical development program in both common and rare diseases for its lead compounds, Bendavia and Ocuvia. Stealth is expanding its mitochondria-targeted… Continue Reading >

    Read the full article
  • January 8, 2015

    Press Release Spotlight

    Stealth BioTherapeutics Announces the Appointment of Mark P. Colonnese as Chief Financial Officer

    Read the full article

    BOSTON, MA, January 8, 2015—(BUSINESS WIRE)—Stealth BioTherapeutics (formerly Stealth Peptides), a clinical-stage biopharmaceutical company developing investigational drugs for the treatment of diseases involving mitochondrial dysfunction, today announced the appointment of Mark P. Colonnese as Chief Financial Officer. Mr. Colonnese brings nearly 30 years of experience in senior management roles leading business growth and financial strategies… Continue Reading >

    Read the full article
  • November 25, 2014

    Press Release Spotlight

    Stealth BioTherapeutics to Present at 26th Annual Piper Jaffray Healthcare Conference on December 3, 2014

    Read the full article

    Newton, Mass. – November 25, 2014 – Stealth BioTherapeutics (formerly Stealth Peptides), a clinical-stage biopharmaceutical company committed to bringing therapies that target mitochondrial dysfunction to patients with severe acute and chronic diseases, today announced that Travis Wilson, Chief Executive Officer, is presenting a corporate overview at Piper Jaffray’s 26th Annual Healthcare Conference. The presentation will… Continue Reading >

    Read the full article

Stealth Biotherapeutics Expands Clinical Development for Mitochondrial Therapies

Funding grows to more than $100M Boston, MA January 9, 2015—(BUSINESS WIRE)—Stealth BioTherapeutics (formerly Stealth Peptides), a clinical-stage biopharmaceutical company developing drug candidates for the treatment of diseases involving mitochondrial dysfunction, today detailed its clinical development program in both common and rare diseases for its lead compounds, Bendavia and Ocuvia. Stealth is expanding its mitochondria-targeted… Continue Reading >

Stealth BioTherapeutics Announces the Appointment of Mark P. Colonnese as Chief Financial Officer

BOSTON, MA, January 8, 2015—(BUSINESS WIRE)—Stealth BioTherapeutics (formerly Stealth Peptides), a clinical-stage biopharmaceutical company developing investigational drugs for the treatment of diseases involving mitochondrial dysfunction, today announced the appointment of Mark P. Colonnese as Chief Financial Officer. Mr. Colonnese brings nearly 30 years of experience in senior management roles leading business growth and financial strategies… Continue Reading >

Stealth BioTherapeutics to Present at 26th Annual Piper Jaffray Healthcare Conference on December 3, 2014

Newton, Mass. – November 25, 2014 – Stealth BioTherapeutics (formerly Stealth Peptides), a clinical-stage biopharmaceutical company committed to bringing therapies that target mitochondrial dysfunction to patients with severe acute and chronic diseases, today announced that Travis Wilson, Chief Executive Officer, is presenting a corporate overview at Piper Jaffray’s 26th Annual Healthcare Conference. The presentation will… Continue Reading >

Leading Cardiovascular Researchers Present Promising Bendavia Findings at 2013 European Society of Cardiology Heart Failure Congress

BOSTON, MA, June 24, 2013—(BUSINESS WIRE)—Stealth Peptides Inc. (Stealth) reported today on promising Bendavia™ findings presented by leading cardiovascular researchers at the European Society of Cardiology (ESC) Heart Failure Congress. Several researchers from Europe and the United States, including Drs. Hani Sabbah and Hazel Szeto, reported on seven recent studies demonstrating Bendavia’s ability to improve… Continue Reading >

Stealth Peptides Reports Successful Clinical Study of Oral Bendavia

Positive Data Broadens Bendavia’s Potential for Chronic Heart Failure and Cardioprotection BOSTON, MA, January 22, 2013–(BUSINESS WIRE)– Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative mitochondrial therapies for cardiovascular disease and its complications, announced today positive oral Bendavia™ clinical results. The Phase I clinical trial demonstrated that oral Bendavia achieved plasma concentrations… Continue Reading >